A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes (SURPASS-3)

The purpose of this study is to compare the effect of the study drug tirzepatide to insulindegludec on blood sugar levels in participants with type 2 diabetes.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Type 2 Diabetes
What the trial is testing?
Insulin Degludec, Tirzepatide
Could I receive a Placebo?
No
Enrollment Goal
1444
Trial Dates
Apr 1, 2019 - Jan 4, 2021
How long will I be in the trial?
The study will last about 59 weeks and may include up to 22 visits.
Trial Phase
III

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participant must have type 2 diabetes mellitus (T2DM)

  • Participant must be on stable treatment dose of metformin, with or without an SGLT-2 inhibitor

  • Participant must be of stable weight

Participants Must Not:

  • Participant must not have type 1 diabetes mellitus (T1DM)

  • Participant must not have pancreatitis

  • Participant must not have disorders with slowed emptying of the stomach contents, or have had any stomach surgeries for the purpose of weight loss

  • Participant must not have acute or chronic hepatitis or symptoms of any other liver disease

  • Participant must not have had a heart attack stroke, or hospitalization for congestive heart failure in the past 2 months

  • Participant must not have been taking weight loss drugs including over-the-counter medications during the last 3 months

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.